TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers at the University Hospital of Bonn and the University of Bonn directly reprogrammed human red blood cell precursors into neural stem cells in a laboratory. They reported that epigenetic clocks in the cells reset gradually, with cells from an 80-year-old showing a molecular age below 20; the work is not a rejuvenation treatment for people.
Researchers in Bonn have directly reprogrammed human red blood cell precursors into neural stem cells in laboratory experiments, reporting that the cells’ epigenetic age markers reset over time. In cells from an 80-year-old donor, the measured molecular age fell below 20 years, according to the team; the finding concerns cells grown and reprogrammed in a test tube, not a proven way to rejuvenate a person.
The work was conducted by researchers from the University Hospital of Bonn and the University of Bonn, and was published in the journal Aging Cell. The team used transcription factors—proteins that influence which genetic instructions a cell reads—to change the developmental identity of blood-cell precursors. The resulting cells were neural stem cells, which can give rise to brain cells.
The researchers measured changes using epigenetic clocks, which estimate cellular age from DNA modifications. These modifications do not alter the DNA sequence itself; they relate to how genetic information is regulated. The team reported that the clocks reset during reprogramming, including in cells from an 80-year-old donor, whose measured molecular age became less than 20 years. That figure describes the clock measurement, not the age or condition of a person.
Unlike an earlier two-step approach—first making a blood cell into a pluripotent stem cell, then directing it toward a neural fate—the Bonn method converted blood-cell precursors directly into neural stem cells. The researchers said the age-marker changes unfolded gradually and could be followed for more than 100 days. The study is by L. J. Berg and colleagues, “Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells,” DOI: 10.1111/acel.70751.
A Slow Model for Cell-Age Research
The reported gradual reset may give researchers a way to investigate how cellular age markers change during reprogramming, rather than observing only a rapid before-and-after shift. The Bonn team said the extended process could help them test which factors or substances speed up or slow down the changes. That is a research opportunity, not evidence that any intervention can safely reverse aging in a person.
The work is also relevant to neuroscience because the cells produced are neural stem cells. Lead researcher Prof. Oliver Brüstle said age is a major risk factor for neurodegenerative diseases such as Alzheimer’s. The study does not show that these reprogrammed cells prevent or treat Alzheimer’s, or that the findings will lead to a clinical therapy. It offers a laboratory model for examining questions about cell identity and age that may inform later research.
As an affiliate, we earn on qualifying purchases.
From Blood Precursors to Neural Cells
Most cells in the body share the same genetic makeup but develop into specialised types with different functions. In their ordinary state, blood cells do not become nerve cells. Laboratory reprogramming can alter a cell’s developmental pathway by using transcription factors to change which genes are active.
The Bonn researchers had previously reported that nerve cells produced through related methods formed connections with existing neurons after transplantation into mouse brains. That earlier result is a separate line of research and does not establish a human treatment. In the current study, the team focused on direct conversion and epigenetic age measurements, not on testing a therapy in people.
“We have directly converted red blood cell precursors into neural stem cells.”
— Prof. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at University Hospital of Bonn
As an affiliate, we earn on qualifying purchases.
What the Cell-Age Measure Shows
The report describes a change in epigenetic clock readings; it does not establish that every feature of a cell’s aging process was reversed. The supplied study summary does not specify how broadly the findings held across donors, how the cells performed over the long term, or whether the molecular-age change translates into lasting functional differences in people.
It is also unclear whether the lab-grown neural stem cells could be used safely or effectively in human treatment. The researchers’ earlier mouse transplantation findings do not answer that question. No clinical benefit for Alzheimer’s or another neurodegenerative disease was reported, and the findings should not be interpreted as a medical intervention.
cell reprogramming laboratory tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the Reprogramming Timeline
The researchers identified the slow timeline as a tool for further experiments: they can track epigenetic clocks over weeks and test which factors alter the pace of reprogramming. The next research steps include clarifying how the cells acquire neural stem-cell identity while age markers change, and whether those changes correspond to durable cellular function.
The study itself does not announce a clinical trial or a treatment plan. Any move toward human use would require further evidence on cell quality, safety, and effectiveness. For now, the immediate development is a laboratory method and a model for studying cellular reprogramming and epigenetic age.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Bonn researchers do?
They used transcription factors to reprogram human red blood cell precursors directly into neural stem cells in laboratory experiments.
What does a molecular age below 20 mean?
It refers to the age estimated by the cells’ epigenetic clock measurements. It does not mean that a donor became biologically younger or that all aspects of cellular aging were reversed.
Was this tested as a treatment in people?
No. The reported work was conducted on cells in a laboratory. The source does not report a human treatment or clinical trial, and it does not show that the process treats neurodegenerative disease.
Why does the gradual process matter?
The researchers said the changes could be tracked for more than 100 days, allowing experiments on factors that may speed up or slow down reprogramming. The study does not yet identify a clinical application.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
